Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apatinib + oxaliplatin + S-1 + docetaxel + lobaplatin
- Development stage
- Unknown
- Lead developer
- Wuhan University
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Intraperitoneal
01
Overview
This combination conversion therapy regimen, developed by Wuhan University, is designed for the treatment of unresectable peritoneal metastases from gastric cancer. The protocol integrates systemic chemotherapy using the SOX regimen (S-1 and oxaliplatin) with the targeted VEGFR-2 tyrosine kinase inhibitor apatinib and hyperthermic intraperitoneal chemotherapy (HIPEC) consisting of docetaxel and lobaplatin. This multi-modal approach aims to reduce the Peritoneal Cancer Index (PCI) to a level where radical gastrectomy and cytoreductive surgery (CRS) become feasible. By combining anti-angiogenic targeted therapy with both systemic and localized cytotoxic agents, the regimen seeks to achieve significant tumor reduction and improve survival outcomes in patients with advanced, unresectable gastric cancer.
- Other names
- SOX plus Apatinib and HIPECConversion therapy for gastric cancer peritoneal metastasesHIPEC and systemic chemotherapy combined with Apatinib
02
Targets
TUBB (Tubulin (alpha and beta subunits))VEGFR2 (Vascular endothelial growth factor receptor 2)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on apatinib + oxaliplatin + S-1 + docetaxel + lobaplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apatinib + oxaliplatin + S-1 + docetaxel + lobaplatin.